The inhibition of MMP - 3 may be a promising therapeutic target for
human central nervous system disease, including SCI,» notes Dr. Yune.
In his Ph.D. project, Dr. Henri Leinonen investigated functional abnormalities of the retina using mouse models of
human central nervous system diseases.
Not exact matches
This species has been shown to demonstrate a progression of Lyme
disease most similar to
humans, particularly related to erythema migrans, carditis, arthritis, and neuropathy of the peripheral and
central nervous systems.
Ultimately, the enhanced understanding of
central nervous system organization that has derived from the research of these three scientists may lead to new and more effective ways to repair
diseased or damaged circuits embedded in the
human brain and spinal cord.
Myelomeningocele: characterization of a surgically induced sheep model and its
central nervous system similarities and differences to the
human disease.
Most recently, Dr. Gringeri was the Chief Operating Officer for Amsterdam Molecular Therapeutics (AMT), a Netherlands - based company engaged in
human gene therapies for orphan
diseases related to metabolic disorders, liver
diseases, blood
diseases, and disorders of the
central and peripheral
nervous systems.
• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled
central nervous system involvement • History of clinically significant cardiac
disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of
human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study
Characteristics of
human disease such as erythema migrans, carditis, arthritis, and neuropathy of the peripheral and
central nervous systems have all been observed in macaques [28].
Thus, the lab's approach may hold great promise for potential treatment of (neuro) inflammation - related
human diseases both in and outside the
central nervous system.
In addition, our studies provide a specific population of
human astrocytes that appears to be particularly suitable for further development towards clinical application in treating the traumatically injured or
diseased human central nervous system.
However, they say the work at least proves the potential for mRNA therapy to successfully treat not only hemophilia B but also other
human disorders, such as hemophilia A (caused by faulty clotting factor VIII) or a variety of
diseases of the liver,
central nervous system, lung and eyes.
This incurable viral
disease affects the
central nervous system of almost all mammals, including
humans if infected.
Rabies Protects against a fatal viral
disease that affects the
central nervous system of all mammals - including
humans.
Rabies is a
disease caused by a virus that can affect the
central nervous system (brain and spinal cord) of any kind of mammal, including
humans.